PATENT CLAIM ANALYSIS

Application Number: 15969109
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "252130"]

Abstract:
Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.

Claim (Index 61):
A method of activating Tie-2 in an eye of a subject in need thereof, the method comprising intravitreally administering to the subject a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a therapeutically-effective amount of a Tie-2 activator,\n wherein the subject has an ocular edema; wherein the therapeutically-effective amount of the Tie-2 activator is from about 1 mg to about 10 mg; wherein after administration of the pharmaceutical formulation to the subject, a visual acuity of the subject increases; wherein the pharmaceutical formulation further comprises a solubilizing agent; and wherein the method further comprises inhibiting VEGF in the eye of the subject.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 93.0
- Lexical Diversity: 1.51515
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13999670', '15355910', '15016599', '13724396', '15705639']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7225653474540554
- 35 USC 102 Novelty (BERT): 0.5218542098620301
- Combined Prediction Score: 0.702494233694853
- Mean Citation Score: 254.32372400000003
- Max Citation Score: 322.6672700000001
- Similarity Product: 229.7074243655425

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test